Head-to-head · Value Score
Gimme Care vs Medro
Two GLP-1 deals, scored on the same six factors. Gimme Care lands a Value Score of 91, Medro a 77. Here's who gives you the honest lower price — and where each one bites back.
Gimme Care
#5 · Grade A · Best Value
Est. first month
$130/mo
Save ~90% vs brand-nameMedro
#97 · Grade B- · Fair Price
Est. first month
From $199/mo (compounded)
Save ~85% vs brand-nameThe verdict
Gimme Care takes it on Value Score, 91 to 77 — an est. $130/mo first month, with no teaser step-up baked in. Medro isn't out of it: Shoppers who want compounded or brand semaglutide/tirzepatide with transparent tiered pricing and no membership, all 50 states.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Gimme Care | Medro |
|---|---|---|
| Value Score | 91 (A) | 77 (B-) |
| Est. first month | $130/mo | From $199/mo (compounded) |
| Save vs brand-name | ~90% | ~85% |
| Semaglutide | $130/mo | From $199/mo (compounded) |
| Tirzepatide | $163/mo | From $299/mo (compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | All 50 states |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Gimme Care
Genuinely cheap on both molecules ($130 / $163) with a LegitScript-certified pharmacy and all-50-state reach.
Why it's a deal
- Low flat price on both molecules ($130 sema / $163 tirz)
- LegitScript-certified pharmacy
- Available in all 50 states
The fine print
- No brand-name option — compounded only
- No oral/sublingual form
Medro
Medro (Medro Health Technologies, Inc.) is a telehealth brand whose GLP-1 program offers compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible, via a partner medical group and…
Why it's a deal
- Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
- LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
- No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
- Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).
The fine print
- Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
- Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
- Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
- Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores Gimme Care is ranked on the Gimme Care alternatives board, and the same list for the other side is on alternatives to Medro.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.